Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abivax SA - American Depositary Shares (NQ: ABVX )

7.550 +0.210 (+2.86%)
Streaming Delayed Price Updated: 3:36 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 196,017
Open 7.160
Bid (Size) 7.510 (6)
Ask (Size) 7.560 (1)
Prev. Close 7.340
Today's Range 7.020 - 7.580
52wk Range 5.495 - 17.02
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Abivax Publishes 2025 Financial Calendar
From Abivax
Via GlobeNewswire
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
From Abivax
Via GlobeNewswire

Performance

YTD
+3.57%
+3.57%
1 Month
+18.52%
+18.52%
3 Month
-15.26%
-15.26%
6 Month
-33.66%
-33.66%
1 Year
-38.11%
-38.11%

More News

Read More
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
From Abivax
Via GlobeNewswire
Abivax Announces a Change to the Composition of its Board of Directors
From Abivax
Via GlobeNewswire
This Veeva Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
From Abivax
Via GlobeNewswire
Abivax presents third quarter 2024 key financial information
From Abivax
Via GlobeNewswire
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
From Abivax
Via GlobeNewswire
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
From Abivax
Via GlobeNewswire
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
From Abivax
Via GlobeNewswire
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
From Abivax
Via GlobeNewswire
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
From Abivax
Via GlobeNewswire
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
From Abivax
Via GlobeNewswire
Abivax presents first-half 2024 financial results
From Abivax
Via GlobeNewswire
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
From Abivax
Via GlobeNewswire
Abivax Provides Operational and Key Program Update
From Abivax
Via GlobeNewswire
AMC Networks, Louisiana-Pacific And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
From Abivax
Via GlobeNewswire
Earnings Scheduled For April 2, 2024
Via Benzinga
Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)
Via ACCESSWIRE
Cross-Border Logistics Provider Globavend Debuts In Quiet Week
Via Talk Markets
Webuy Shares Soar In Market Debut
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.